FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology and biotechnology. There are presented: an isolated antibody or its variant specifically recognising PCSK9, and a based pharmaceutical composition for lowering LDL-cholesterol. There are described: using for lowering blood cholesterol and/or LDL; reducing an incidence rate and/or correcting abnormal cholesterol and/or LDL; using for preparing a drug for lowering blood cholesterol and/or LDL; reducing the incidence rate and/or correcting abnormal cholesterol and/or LDL. There are disclosed versions of cell lines producing PCSK9 antibody or its antigen-binding portion and deposited in the American typical culture collection (ATCC) under Nos. PTA-8986, ATCC PTA-8984, ATCC PTA-8983, respectively. What is described is a coding nucleic acid and a host cell for producing the based antibody.
EFFECT: invention provides PCSK9 agonist antibodies that can find application in medicine for lowering cholesterol.
18 cl, 24 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
| TREATING WITH ANTI-PCSK9 ANTIBODIES | 2012 |
|
RU2576034C2 |
| ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING | 2011 |
|
RU2570729C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| PCSK9 VACCINES | 2015 |
|
RU2698971C2 |
| VACCINE | 2012 |
|
RU2640258C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
